FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

VaxGen sells anthrax vaccine to its old rival

Tools

Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to $8 million in milestones.

VaxGen began to founder in 2006 when the government revoked an $877 million contract for the VaxGen vaccine after the company failed to start a human trial on schedule. Now Emergent, which makes the only FDA-approved anthrax vaccine now available, says it plans to advance the experimental vaccine.

VaxGen, which once had more than 200 employees, has been reduced to a staff of about six after a planned merger with Raven biotechnologies fell through.

- here's VaxGen's release on the deal

Related Articles:
Struggling VaxGen sells anthrax vaccine to rival
VaxGen faces possible liquidation after merger flops
Shareholders stymie VaxGen, Raven merger
Momentum builds for VaxGen, Raven merger
VaxGen slashes staff--again

Twitter   Facebook   LinkedIn   StumbleUpon  
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Vaccine   anthrax   VaxGen   Emergent BioSolutions  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.